Join AcuraStem's CEO, Sam Alworth, at the forthcoming 2023 BIO International Convention in Boston from June 5-8, 2023. AcuraStem is at the cutting edge of developing treatments for neurodegenerative diseases, including sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).
Leveraging the team's strong expertise in antisense oligonucleotide (ASO) technology, AcuraStem accelerates the journey of potential treatments towards clinical trial phases. Further, its proprietary iNeuroRx® platform stands as an industry-leading tool for disease modeling, fueling the discovery of innovative, effective, and widely applicable treatment strategies.
Joining the BIO International Convention means becoming part of a global gathering that draws over 14,000 leaders from the biotechnology and pharmaceutical sectors. This four-day event, focused on intensive networking, creates a vibrant platform for discovering new opportunities and fostering promising partnerships. It features in-depth discussions on the current state and future prospects of biotech, spanning topics such as therapeutic frontiers, the business aspects of biotech, regulatory and policy landscapes, and human capital considerations.
Register now to glean valuable insights on how to navigate the complex biotechnology landscape, establish meaningful collaborations, and contribute to advancing patient care.
To find out more go to: bio.org/events/bio-international-convention